These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38141462)

  • 21. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
    Torrisi R; Marrazzo E; Agostinetto E; De Sanctis R; Losurdo A; Masci G; Tinterri C; Santoro A
    Crit Rev Oncol Hematol; 2021 Apr; 160():103280. PubMed ID: 33667658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
    Leichsenring J; Vladimirova V; Solbach C; Karn T; Ataseven B; Sinn BV; Barinoff J; Müller V; Blohmer JU; Schem C; Engels K; Marmé F; Fisseler-Eckhoff A; Fasching PA; Stickeler E; van Mackelenbergh M; Denkert C; Stenzinger A; Loibl S; Gröschel S
    BMC Cancer; 2022 Oct; 22(1):1040. PubMed ID: 36195836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
    Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study.
    Baez-Navarro X; van Bockstal MR; Jager A; van Deurzen CHM
    Pathology; 2024 Apr; 56(3):334-342. PubMed ID: 38341307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.
    Shi Z; Liu Y; Fang X; Liu X; Meng J; Zhang J
    Sci Rep; 2024 Jul; 14(1):16899. PubMed ID: 39043756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
    Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
    Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers.
    de Nonneville A; Houvenaeghel G; Cohen M; Sabiani L; Bannier M; Viret F; Gonçalves A; Bertucci F
    Eur J Cancer; 2022 Nov; 176():181-188. PubMed ID: 36257173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.
    Wang W; Zhu T; Chen H; Yao Y
    Clin Transl Oncol; 2023 Jun; 25(6):1673-1681. PubMed ID: 36586066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
    Katayama A; Miligy IM; Shiino S; Toss MS; Eldib K; Kurozumi S; Quinn CM; Badr N; Murray C; Provenzano E; Callagy G; Martyn C; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Oyama T; Shaaban AM; Ellis I; Lee AHS; Rakha EA
    Mod Pathol; 2021 Jul; 34(7):1271-1281. PubMed ID: 33526875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.